Kura Oncology KURA
NASDAQ KURA
$10.86 +0.15 (+1.40%)
As of: Oct 1, 2026 · 10:49 AM EDT

Kura Oncology (KURA) EBIT Margin (2025 - 2026)

Updated

Kura Oncology (KURA) reported EBIT Margin of -349.77% for Q2 2026, up 125.55 percentage points from -475.31% a year earlier and up 81.74 percentage points from the prior quarter.

Analysis

Kura Oncology (KURA) EBIT Margin (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Kura Oncology's EBIT Margin came in at -396.41%; for FY2025, it came in at -449.94%, down 91.40 percentage points from FY2024.

  • By year, EBIT Margin came in at -358.55% in FY2024.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -431.51% (Q1 2026), -464.82% (Q4 2025) and -355.29% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 28.21%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 37.86%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -3.52%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 32.97%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 20.57%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 34.95%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -133.21%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 37.40%
10 Kura Oncology 952.70 Mn 952.70 Mn 20.63 Mn -349.77%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -349.77%
Mar 31, 2026 -431.51%
Dec 31, 2025 -464.82%
Sep 30, 2025 -355.29%
Jun 30, 2025 -475.31%
Mar 31, 2025 -458.61%
API Access

Kura Oncology EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=KURA&period=max&api_key=YOUR_API_KEY